Telix Pharmaceuticals Limited (ASX:TLX) People
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| David Gill Other companies: Y mAbs Therapeutics (Director · Since at least Sep 20, 2018); Evolus, Inc. Common Stock (Director · Since at least Feb 12, 2018); Strongbridge Biopharma plc (Director · Sep 3, 2019 – Oct 5, 2021 · Past); STRATA Skin Sciences, Inc. (Director · May 30, 2018 – Nov 22, 2019 · Past); Melinta Therapeutics Inc (Director · May 25, 2018 – Jun 11, 2019 · Past); Ocugen, Inc. (Director · Dec 9, 2016 – Jun 15, 2018 · Past); Cempra Inc (Director · Jan 1, 2016 – Jan 3, 2017 · Past); EndoChoice Holdings Inc (President and CFO · Aug 14, 2015 – Nov 22, 2016 · Past) | Chair & Independent Non-Executive Director · Since Apr 2, 2026 |
| William Jellison Other companies: Medtronic plc. (Director · Since at least Aug 19, 2025); Masimo Corporation (Director · Since at least Sep 19, 2024); Anika Therapeutics Inc. (Director · Since at least May 28, 2024); Avient Corporation (Director · Since at least Oct 7, 2015); Stryker Corporation (VP and CFO · Apr 22, 2013 – Feb 11, 2015 · Past); Dentsply Sirona Inc. (Sr. VP & C.F.O. · Feb 13, 2006 – Apr 12, 2013 · Past) | Independent Non-Executive Director · Since at least May 11, 2026 |
| Maria Rivas Other companies: The Cooper Companies, Inc. (Director · Since at least Jul 1, 2021); Medidata Solutions Inc (Director · Oct 19, 2018 – Oct 28, 2019 · Past) | Independent Non-Executive Director · Since at least May 11, 2026 |
| Annie Kasparian | Investor Relations · Since at least Sep 1, 2026 |
| Charlene Jaw Associate | Director Investor Relations · Since at least Jun 23, 2026 |
| Christian Behrenbruch | Managing Director & Group Chief Executive Officer · Since at least Mar 18, 2026 |
| Christian Krautkramer | Group General Counsel · Since at least Nov 5, 2026 |
| Craig Ulrick | Chief Information Officer · Since at least Nov 5, 2026 |
| Darren Patti | Group Chief Operating Officer · Since at least Jun 4, 2025 |
| Darren Smith | Group Chief Financial Officer · Since at least Mar 18, 2026 |
| David Cade | Group Chief Medical Officer · Since at least Mar 18, 2026 |
| Jann Skinner | Independent Non-Executive Director · Since at least Mar 18, 2026 |
| Kenneth Clarke | SVP, Global Regulatory Affairs · Since at least Nov 5, 2026 |
| Kevin Richardson | Telix Precision Medicine · Until May 6, 2026 · Past |
| Kyahn Williamson | SVP, Investor Relations & Corporate Communications · Since at least Jun 23, 2026 |
| Marie McDonald | Independent Non-Executive Director · Since at least Mar 18, 2026 |
| Mark Nelson | Independent Non-Executive Director · Since at least Mar 18, 2026 |
| Mary Jessel | Group Chief of Clinical Affairs · Since at least May 20, 2025 |
| Meredith Crowe | SVP, Global People & Culture · Since at least Nov 5, 2026 |
| Paul Schaffer | SVP, Research & Development · Since at least Nov 5, 2026 |
| Radu Ciocan | SVP, TMS Radiopharmaceutical Operations · Since at least Nov 5, 2026 |
| Raphaël Ortiz | Telix International · May 1, 2026 – May 6, 2026 · Past |
| Richard Valeix | Telix Therapeutics · Until May 6, 2026 · Past |
| Thorsten Melcher | SVP, Global Business Development and Alliance Management · Since at least Nov 5, 2026 |
| Tom Fromm | SVP, Corporate Sales · Since at least Nov 4, 2026 |